Trial Profile

A Cancer Research UK Phase I Trial of LY3143921 Hydrate (a Cdc7 Inhibitor) Given Orally in Adult Patients With Advanced Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY-3143921 (Primary)
Indications Advanced breast cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; First in man

Most Recent Events

20 Jul 2026 Status changed from active, no longer recruiting to completed.
17 Oct 2023 Planned End Date changed from 31 Jul 2023 to 28 Feb 2027.
17 Oct 2023 Planned primary completion date changed from 31 Jul 2023 to 28 Feb 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com